Want to see KR:207940 full AI Analyst Report?

SAMSUNG BIOLOGICS Co., Ltd. (207940) Price & Analysis

1 Followers

207940 Stock Chart & Stats

$1366000.00

-$6,000.00(-0.44%)

Oct 29, 2026

―

Day’s Range― - ―

52-Week Range$1,150,000.00 - $1,973,601.65

Previous CloseN/A

VolumeN/A

Average Volume (3M)N/A

Market Cap

₩66.01T

Enterprise Value$63.37T

Total Cash (Recent Filing)₩2.19T

Total Debt (Recent Filing)₩1.24T

Price to Earnings (P/E)35.3

Beta0.16

Next Earnings

Jan 27, 2027

EPS Estimate

11,137.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)42889.19

Shares Outstanding48,108,982

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG Ratio0.68

Price to Book (P/B)10.52

Price to Sales (P/S)17.20

P/FCF Ratio91.55

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₩1,550,000.00

Price Target Upside― Downside

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)39,528.76

Revenue Forecast (FY)₩5.54T

Bulls Say, Bears Say

Bulls Say

Strong Growth And MarginsAccelerating revenue and very high profitability indicate strong demand for Samsung Biologics’ services and meaningful operating scale. If sustained, this combination can support reinvestment, strengthen competitive positioning, and expand earnings capacity over the next several quarters.

Conservative Balance SheetLow leverage gives Samsung Biologics financial flexibility to invest in capacity and strategic initiatives without placing excessive pressure on interest costs or liquidity. It also improves resilience if industry conditions weaken, while solid returns on equity indicate productive capital use.

Long-term Revenue VisibilityThe multi-year manufacturing agreement strengthens the order book and provides meaningful revenue visibility through 2033. Long-duration customer commitments can support facility utilization, improve planning confidence, and reinforce Samsung Biologics’ position as a major global biologics manufacturer.

Bears Say

Uneven Free Cash Flow HistoryCurrent cash generation is strong, but prior negative and weak free-cash-flow periods show that accounting profits have not converted consistently across cycles. This may make internally funded expansion less predictable and increases the importance of disciplined investment and working-capital management.

Equity Dilution From Expansion FundingThe rights offering provides funding for new facilities and corporate investments, but issuing nearly 4.9% more shares can dilute existing ownership if growth returns do not adequately offset the enlarged equity base. Expansion also raises the need for effective capital allocation and execution.

CDMO Competition And Execution RiskSamsung Biologics faces structural uncertainty as competitors add capacity, pharmaceutical clients may bring production in-house, and tariffs or regulation could affect global demand. New businesses such as ADCs, CRO services, and peptides also require successful execution before contributing durable growth.

SAMSUNG BIOLOGICS Co., Ltd. News

Samsung Biologics Posts Strong Q3 Revenue and Operating Profit Despite Net Income Decline

SAMSUNG BIOLOGICS Co., Ltd. ( ($KR:207940) ) just unveiled an announcement. Samsung Biologics reported strong third-quarter 2026 provisional...

9d ago

Samsung Biologics Sets Provisional Price for Paid‑In Capital Increase

SAMSUNG BIOLOGICS Co., Ltd. ( ($KR:207940) ) just unveiled an update. Samsung Biologics has set a provisional new...

29d ago

Samsung Biologics share offering lays out ambitious CDMO expansion and mounting risk factors

SAMSUNG BIOLOGICS Co., Ltd. ( ($KR:207940) ) just unveiled an update. Samsung Biologics Co., Ltd. has filed an...

2M ago

Samsung Biologics Secures KRW 350.8 Billion Long-Term Manufacturing Deal With European Pharma Client

The latest announcement is out from SAMSUNG BIOLOGICS Co., Ltd. ( ($KR:207940) ). Samsung Biologics has signed a...

2M ago

Samsung Biologics Confirms Stable Samsung Group Control Despite Minor Share Adjustments

SAMSUNG BIOLOGICS Co., Ltd. ( ($KR:207940) ) has issued an update. Samsung Biologics has reported an updated shareholding...

2M ago

Samsung Biologics Plans KRW 3 Trillion Rights Offering to Expand Biologics Capacity

The latest announcement is out from SAMSUNG BIOLOGICS Co., Ltd. ( ($KR:207940) ). Samsung Biologics has approved a...

2M ago

207940 FAQ

What was SAMSUNG BIOLOGICS Co., Ltd.’s price range in the past 12 months?

SAMSUNG BIOLOGICS Co., Ltd. lowest stock price was $1150000.00 and its highest was $1973601.65 in the past 12 months.

What is SAMSUNG BIOLOGICS Co., Ltd.’s market cap?

SAMSUNG BIOLOGICS Co., Ltd.’s market cap is ₩66.01T.

When is SAMSUNG BIOLOGICS Co., Ltd.’s upcoming earnings report date?

SAMSUNG BIOLOGICS Co., Ltd.’s upcoming earnings report date is Jan 27, 2027 which is in 89 days.

How were SAMSUNG BIOLOGICS Co., Ltd.’s earnings last quarter?

SAMSUNG BIOLOGICS Co., Ltd. released its earnings results on Oct 21, 2026. The company reported $8448.727 earnings per share for the quarter, missing the consensus estimate of $9799.289 by -$1350.562.

Is SAMSUNG BIOLOGICS Co., Ltd. overvalued?

According to Wall Street analysts SAMSUNG BIOLOGICS Co., Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does SAMSUNG BIOLOGICS Co., Ltd. pay dividends?

SAMSUNG BIOLOGICS Co., Ltd. does not currently pay dividends.

What is SAMSUNG BIOLOGICS Co., Ltd.’s EPS estimate?

SAMSUNG BIOLOGICS Co., Ltd.’s EPS estimate is 11,137.25.

How many shares outstanding does SAMSUNG BIOLOGICS Co., Ltd. have?

SAMSUNG BIOLOGICS Co., Ltd. has 48,108,982 shares outstanding.

What happened to SAMSUNG BIOLOGICS Co., Ltd.’s price movement after its last earnings report?

SAMSUNG BIOLOGICS Co., Ltd. reported an EPS of $8448.727 in its last earnings report, missing expectations of $9799.289. Following the earnings report the stock price went up 1.869%.

Which hedge fund is a major shareholder of SAMSUNG BIOLOGICS Co., Ltd.?

Currently, no hedge funds are holding shares in KR:207940

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SAMSUNG BIOLOGICS Co., Ltd.

Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.

SAMSUNG BIOLOGICS Co., Ltd. (207940) Earnings & Revenues

Historic Earnings Reports

207940 Stock 12 Month Forecast

Average Price Target

$1,550,000

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1367713":"$1,367,713","1576298":"$1,576,298","1784883":"$1,784,883","1472005.5":"$1,472,005.5","1680590.5":"$1,680,590.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1550000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2M</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1550000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2M</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1550000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2M</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1367713,1472005.5,1576298,1680590.5,1784883],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1419364.3,1429413.2,1439462.1,1449511,1459559.9000000001,1469608.8,1479657.7,1489706.6,1499755.5,1509804.4,1519853.3,1529902.2,1539951.1,{"y":1550000,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1419364.3,1429413.2,1439462.1,1449511,1459559.9000000001,1469608.8,1479657.7,1489706.6,1499755.5,1509804.4,1519853.3,1529902.2,1539951.1,{"y":1550000,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1419364.3,1429413.2,1439462.1,1449511,1459559.9000000001,1469608.8,1479657.7,1489706.6,1499755.5,1509804.4,1519853.3,1529902.2,1539951.1,{"y":1550000,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1469129.6,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1784882.899,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1637880.8,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1683570.6,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1699462.8,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1766010.899,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1561400,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1460087.8,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1367714.899,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1386586.8,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1474986.6,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1509750.6,"date":1788220800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1419364.3,"date":1790812800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >